China-based Thederma has announced that its TAP-1503 cream has been granted approval by the National Medical Products Administration (NMPA) with priority review status. The drug, containing 1% tapinarof as a small molecule chemical drug, is now approved for the treatment of atopic dermatitis (eczema) in children over two years old and adults, under the trade name ZeLiMei.
ZeLiMei: A Non-Hormonal Topical Treatment with a Novel Mechanism
ZeLiMei is recognized as the world’s first approved aromatic hydrocarbon receptor (AhR) modulator for the treatment of atopic dermatitis in children over two years old and adults. This non-hormonal topical treatment offers a new mechanism of action and target, providing an alternative to traditional treatments.
Clinical Study Results and Safety Profile
Pivotal clinical study results from China demonstrate that ZeLiMei cream has a rapid onset and high efficacy, particularly for children suffering from atopic dermatitis. Additionally, the cream has shown a good safety profile, making it a promising addition to the treatment options for this common skin condition.-Fineline Info & Tech
